Cross-Sector entity
TB-500 is most often covered alongside BPC-157, which appears in 5 of these 5 stories. Coverage clusters in regulation, which accounts for 3 of those 5, with the remainder spread across 1 other category. TB-500 appears in 5 tracked Cross-Sector stories published from August 1, 2026 through August 3, 2026.
5 verified stories tracked
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 80 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
TB-500 is most often covered alongside BPC-157, which appears in 5 of these 5 stories. Coverage clusters in regulation, which accounts for 3 of those 5, with the remainder spread across 1 other category. TB-500 appears in 5 tracked Cross-Sector stories published from August 1, 2026 through August 3, 2026. Each carries 2.4 original sources on average. Negative sentiment appears in 0% of the tracked stories.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TB-500. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
A key FDA panel vote could expand legal access to BPC-157, TB-500, and four other peptides through compounding pharmacies. Vanta is positioning its telehealth and pharmacy network to deliver these therapies to consumers seeking longevity care.
The FDA advisory committee recommended six peptide substances for the 503A Bulks List, a critical regulatory step that could reshape compounding pharmacy law. Vanta is proactively building a compliant telehealth and manufacturing infrastructure, anticipating the rule change.
Source: tennesseedaily.com · californiatelegraph.com
An FDA advisory committee voted 8-6 to recommend allowing pharmacy compounding of unapproved peptides like BPC-157, raising urgent questions about patient safety, telehealth marketing practices, and regulatory integrity.
Source: santafenewmexican.com · texarkanagazette.com
